

Product Data Sheet

ATL 1102 sodium

Cat. No.: HY-153481A

Target: Integrin

Pathway: Cytoskeleton

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

ATL 1102 (sodium)

BIOLOGICAL ACTIVITY

Description

ATL 1102 sodium is a novel second-generation antisense oligonucleotide to CD49d mRNA

REFERENCES

[1]. Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on a4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One. 2017;12(11):e0187684.

[2]. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsingremitting MS [published correction appears in Neurology. 2015 Jan 6;84(1):105]. Neurology. 2014;83(20):1780-1788.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Screening Libraries

Inhibitors

Proteins

Page 1 of 1